Background. Fungal surveillance cultures (FSCs) have been proposed as predictors for development of invasive fungal disease (IFD) and identifiers of the causative organism, although data supporting these are limited and predate universal initiation of antifungal prophylaxis. We aimed to define the epidemiology of fungal colonization and investigate the utility of FSCs for predicting IFD in recipients of pediatric hematopoietic stem cell transplantation (HSCT).
Invasive fungal diseases (IFDs) remain a significant cause of morbidity and mortality in immunocompromised populations, especially among patients with hematological malignancies and recipients of hematopoietic stem cell transplantation (HSCT) [1] [2] [3] [4] . Antifungal prophylactic treatment with azole antifungals, commonly used in the post-transplant period since 1990, has resulted in a reduction in the rates of IFDs after HSCT, with a shift in the epidemiology, mainly decreased rates of candidiasis with increases in infections caused by Aspergillus spp., Mucoraceae, and other molds observed at some centers [2, [5] [6] [7] [8] [9] [10] . In a recent study reporting rates of infection in pediatric post-HSCT patients, the authors still found 4% of patients developed invasive candidiasis, 6% developed aspergillosis, and another 6% had probable IFD based on symptoms and radiographic imaging [1] .
One of the major obstacles to the prevention and treatment of IFDs in immunocompromised patients is the difficulty in diagnosing early stages of infection. The clinical signs and symptoms associated with fungal disease are well known but are nonspecific and generally not helpful in distinguishing the condition from bacterial or viral diseases. As a result, autopsy studies have shown that the majority of fatal IFDs are diagnosed postmortem [11, 12] . Mortality associated with fungal infections is high in the patient with compromised immunity, with IFDs causing 53% of infection-related mortality in a recently published large cohort of pediatric HSCT recipients [1] .
There is no consensus about the most effective strategy to reduce the morbidity and mortality related to IFDs in high-risk populations. Protocols range from a preemptive approach, which focuses on early detection, to broad empiric antifungal treatment for all patients at high risk for IFDs [2, 4, 13, 14] .
Fungal surveillance cultures (FSCs) have been proposed to predict development of IFDs and to identify the causative organism. A limited number of studies have shown conflicting results with regard to the clinical value of FSCs [15] [16] [17] [18] [19] [20] [21] . Although some studies have showed fungal surveillance data to be of value in early diagnosis and management of IFDs, these data were collected before general use of azole antifungal prophylaxis [15, 17] , and other authors have challenged the utility of the procedure [18, 20, 21] . Practice guidelines issued by several professional societies, including the Infectious Diseases Society of America, concluded that performing fungal surveillance cultures is not indicated for asymptomatic HSCT recipients [14, 22] . Nonetheless, performing FSCs is part of routine post-transplant care in many centers. In this study, we evaluated the clinical value of our own practice of performing weekly FSCs in HSCT patients. Additionally, we ascertained the relevance of our findings by surveying HSCT providers across the country about their FSC practice.
METHODS
All components of the study were approved by the Committee on Clinical Investigation at Boston Children's Hospital.
Setting and FSC Practice
Boston Children's Hospital is a quaternary-care pediatric hospital with 396 inpatient beds. The joint Pediatric Stem Cell Transplantation Program at Dana-Farber Cancer Institute and Boston Children's Hospital Cancer Center is one of the largest in the nation, performing about 95 stem cell transplants each year. Starting at day of admission, all patients are routinely cultured for fungi at 3 sites (nares, throat, and stool). This procedure is repeated weekly through engraftment until discharge and then at the discretion of the provider at readmissions. During the study period, institutional practice consisted of treatment with prophylactic antifungals during stem cell conditioning and through discharge for patients undergoing autologous transplant. Patients undergoing allogeneic transplant received fungal prophylaxis through discontinuation of corticosteroid prophylaxis or until day +75 if corticosteroids were not used. Fluconazole was the most commonly used antifungal for prophylaxis (83.6% of patients) because the study period preceded our institutional switch to voriconazole for this purpose (Supplementary Appendix 1).
FSC Data Collection and Chart Review
The [23] were included in the analysis.
Culture Methods
Fungal cultures were performed using Sabouraud dextrose agar. Plates were cultured for 5 days at 35°C with 5% carbon dioxide. This incubation period was selected to detect most yeast, Aspergillus, and Mucoraceae but will not detect some slower-growing fungi. Plates were inspected daily for growth with colony morphology suggestive of fungi. Molds were identified by morphology using lactophenol cotton blue stain. Yeast were first tested by the germ-tube test for identification of Candida albicans. Yeast that did not form a germ-tube were identified by morphology on cornmeal agar and biochemical testing using the yeast identification system for the Vitek 2.
Survey
To assess prevalence of use of FSCs in different institutions and the relevance of our findings to other HSCT centers in the country, we conducted a Web-based survey of FSC practice among pediatric transplant providers. The survey was developed and distributed and data were collected and managed using REDCap electronic data capture tools hosted at Boston Children's Hospital. The electronic questionnaire was distributed to 72 pediatric HSCT providers who had participated in a separate clinical trial, and the link was active for 7 days. The survey contained no identifying data except for the name of the medical center. To determine institutional policies, we compared responses from providers at the same institution(s). For the question asking providers to rate the clinical usefulness of performing FSCs on a scale of 0-100, we report the mean rating of providers from the same institution. Data captured included information about whether the providers routinely perform FSCs after HSCT, frequency of FSCs, sites swabbed, and duration of screening. In addition, participants were asked to rate the usefulness of performing FSCs on a sliding visual scale of 0-100.
Data Analysis
Statistical analyses were performed using SPSS statistical software version 18. The results of numerical measurements are reported using their means and standard deviations with the medians and ranges, whereas the results of categorical measurements are reported using percentages. Continuous variables were summarized with medians, interquartile ranges, and range and compared between groups using the Mann-Whitney test. Fisher exact test was used to examine the differences in categorical parameters between groups.
The rates of IFD per 1000 patient days at risk were estimated for patients with and without a positive preceding FSC. Patients were considered at risk from time of transplant until the end of the study period, the patient died, or the outcome (IFD) occurred. Patients with a positive FSC contributed days to the FSC-negative group until the first positive FSC and thereafter contributed days to the FSC-positive group. Confidence intervals for IFD rates were constructed using exact Poisson methods.
RESULTS

Fungal Surveillance Cultures
A total of 5618 FSCs from 360 discrete HSCT patients were processed in our lab between 2007 and 2011 ( Table 1 ). The median number of cultures obtained per patient was 16, with a range of 1-72. A total of 232 patients (64.4%) had at least 1 positive FSC. Stool samples had the highest rate of positive results (n = 569 of 1874 stool cultures obtained; 30.3%), whereas the rate in nares cultures was only 0.9% (n = 17 of 1874). Table 1 shows the number of cultures obtained from different anatomical sites and the number of positive cultures.
The most commonly recovered fungi were Candida species, with Candida albicans and Candida glabrata being the most common among these (Table 2) . Saccharomyces cerevisiae and Mucoraceae were less common, and no Aspergillus species were detected.
Invasive Fungal Disease
A total of 30 (8.3%) patients met our definition for IFDs: 10 (33.3%) with C. albicans; 8 (26.6%) with C. lusitaniae; 2 (6.4%) each with C. glabrata, C. krusei, and C. tropicalis; 3 (9.6%) with A. fumigatus; and 1 (3.2%) each with Penicillium species, Fusarium species, and Scopulariopsis species.
Associations Between FSC and IFD
Of the 232 patients with positive FSC, 17 (7.9%) developed an IFD, whereas among the 128 patients with negative FSC, 13 developed an IFD (10.1%, P = .43). Antifungal coverage was changed in 69 of the 232 (29.9%) patients with positive FSC within 48 hours of the positive result. Of these 69 patients, 6 (8.6%) went on to develop an IFD; 2 of these 6 patients developed an IFD with the same species as was detected in the FSC. Of the 163 patients in whom antifungal coverage was not changed within 48 hours after positive culture result, 11 developed an IFD (6.7%); 3 of these 11 patients developed an IFD with the same species as was detected in the FSC. There was no significant difference in the IFD rate in FSC-positive patients between patients that had a change in antifungals and those that did not (P = .59). Among the 17 patients with positive nares FSC, none developed an IFD. Among the 247 patients with positive throat FSC, 5 developed an IFD; in 2 of these 5 cases, the IFD was with the same pathogen that was recovered in the FSC. Both of the patients also had stool FSC growing the same organism. In both of these patients, antifungal treatment coverage was changed after the positive FSC. One patient went on to develop an IFD a week later in spite of treatment; the second developed an IFD 18 months after the transplantation.
Among the 569 patients with positive stool FSC, 14 developed an IFD; in 8 of these 14 cases, the IFD was with the same organism that was recovered by FSC. In 6 cases, the organism was sensitive to the prophylactic antifungal administered. Nevertheless treatment was changed in 3 patients. In 2 patients, the organism recovered was not susceptible to fluconazole, and in 1 patient antifungal prophylaxis was changed.
In total, our study population had 328 500 days of follow-up when patients were at risk for IFDs: 101 840 days of FSC-negative and 226 660 days of FSC-positive time. The rate of IFD per 1000 days in the FSC-negative group was 0.127 (95% confidence interval [CI], .072-.229), which was not different from the rate in the FSC-positive group of 0.075 (95% CI, .043-.120). When patients with positive FSCs were divided into those whose antifungal treatment was changed within 48 hours of the FSC result and those who had no treatment change, the rates of IFD per 1000 days were 0.071 (95% CI, .041-.121) and 0.089 (95% CI, .052-.13), respectively ( Figure 1 ).
Survey Results
The electronic questionnaire was distributed to 72 pediatric HSCT providers across the country, and we received 51 complete responses (70.8% response rate) from HSCT providers at 40 institutions in the United States and Canada (Table 3) . There were no conflicting answers about routine practice of FSCs between providers in the same institutions. Overall, 16 (40%) pediatric HSCT programs routinely perform FSCs after transplant. Stools and then throats are the most commonly cultured sample types, with nares, groin, and axilla being cultured at fewer institutions. Cultures were performed weekly at all institutions that performed FSCs. Practices for stopping these cultures after HSCT varied between institutions. When asked how a positive FSC would affect management of an otherwise asymptomatic patient, 6 providers from 4 (25%) programs would change the prophylactic antifungal treatment to achieve optimal coverage of the colonizing organism, 8 (50%) would not change management unless the patient became symptomatic, in which case they would target the colonizing organism, and 4 (25%) providers claimed that a positive FSC would not change the management of the patient in any way. When asked to rate the clinical usefulness of FSCs in guiding empiric antifungal treatment in pediatric HSCT patients, the median was 24 (range, 0-96; interquartile range, 12.5-63). There was no difference in results when comparing the ratings of all providers or analyzing only the subgroup of providers that routinely perform FSCs in their institution (P = .39).
DISCUSSION
To the best of our knowledge, this is the first published analysis of FSCs in pediatric HSCT patients in the era of azole antifungal prophylaxis. We found that there is great variability in the yield of the FSCs depending on the body site tested. Notably, in reviewing 5 years of routine cultures there was not a single case in which the nares cultures provided any relevant clinical information. Similarly, throat cultures added little value, if any, to the treatment of patients. There were only 2 patients with throat cultures positive for the same organism that later caused an IFD, and in both cases the same pathogen was also recovered from stool cultures. The stool cultures had the highest yield in terms of recovery of colonizing fungi, with 30.3% positivity. However, the clinical utility of these positive FSC results is unclear. There was no difference in the rates of IFD between patients with or without positive FSC. This was true regardless of whether antifungal therapy was changed after the initial positive FSC result. We cannot exclude that there may be some value in knowing the colonizing fungal flora in HSCT patients because that information could be used to guide empiric antifungal therapy in patients with suspected or known IFDs. Recent studies suggest that fungal infections are equally prevalent in the immediate post-transplant period and in the late phase, up to several years after the transplant [1, 13, 24] . Our study focused on the period of hospital admission after HSCT, so we did not evaluate whether treatment decisions in patients presenting in the late phase were influenced by previous FSCs. However, it seems unlikely that providers would base a treatment decision on a surface swab that was performed many months or even years earlier.
The distribution of organisms isolated in this study is compatible with previous reports [3, 13] that were performed before use of azole antifungal prophylaxis was common in HSCT patients. Although usual practice at our institution was to use fluconazole for prophylaxis in HSCT patient in the posttransplant period, many of the fungi isolated in the FSCs are species that are usually susceptible to fluconazole. The most commonly isolated organism was C. albicans, and other fungi that are usually fluconazole susceptible also made up a significant number or the isolates (eg, C. parapsilosis and C. lusitaniae). Interestingly, no isolates of Aspergillus were detected in FSCs, although 3 patients developed IFDs with this pathogen. One of these patients had 72 FSCs performed before developing pulmonary aspergillosis. These data suggest that FSCs are insensitive for predicting and detecting invasive aspergillosis in HSCT patients. This is especially important considering that in most series aspergillosis is the second most frequent cause of fungal-related morbidity in children receiving cancer treatment or HSCT [4] .
Although the advantages of performing FSCs are unclear, there are several possible disadvantages associated with their use. First, the cost is not insignificant. In our institution, the charge for a single FSC during the study period was $80, for a total of $449 440 charged during the 5-year period. Second, if providers alter antifungal therapy in response to a positive FSC, this could lead to overuse of broad spectrum antifungals, development of associated toxicities, and development of antifungal resistance. Indeed, our survey results indicated that a quarter of Until discharge and whenever patient is readmitted 6 (37. respondents would change prophylactic treatment of an asymptomatic patient to target the organism detected in the FSC. Finally, if FSCs are used to guide empiric therapy of suspected fungal infections in the absence of a specific etiology, inappropriate antifungal treatment might be selected because there was low concordance between the fungi detected in a patient's FSC and that patient's IFD. Half of those responding to our survey indicated that they would target the organism detected in an FSC in a symptomatic patient. This should be taken into account when deciding whether to pursue routine FSCs in this high-risk population. The relevance of this study is underscored by our finding that 40% of HSCT centers surveyed are performing weekly FSCs as part of their routine post-transplant care. This practice is inconsistent with the conclusions of several professional societies, including the Infectious Diseases Society of America, that FSC is not indicated for asymptomatic HSCT patients [14, 22] . Perhaps the most interesting observation in the survey is the fact that many providers find FSCs to be of very limited value, a view that is shared both by those that routinely use these cultures in clinical practice and those that do not use FSCs.
This study is subject to a number of limitations. First, this was a single-center retrospective review of laboratory and clinical data. Our descriptive data on the results of the FSCs performed in our institution are not influenced by the usual limitations of this type of study such as information bias because the computer database will objectively identify and report results from all FSCs based on a unique identifier. With regard to retrospective collection of clinical data, there are some potential caveats. In this study we defined IFDs in accord with the revised definitions of invasive fungal infections as proposed by the EORTC/MSG Consensus Group [23] . We included patients with proven or probable IFDs in our analysis, excluding the patients with possible IFDs. This might potentially have led us to underestimate the true number of patients with IFDs. We did, however, collect information about diagnoses given to patients at subsequent visits and mortality data throughout the 5-year period. Given the high mortality associated with IFDs, we think it unlikely that we have overlooked a significant number of cases because they would have to have been undiagnosed and untreated for IFD and have survived the study period. Indeed, in 2 cases the IFD was diagnosed postmortem. The overall rate of IFD described in our data of 8.3% is compatible with previously described rates of IFD in HSCT patients [1, 3, 24] . Another unknown in the context of our data is the reasoning behind the change in antifungal treatment in some patients with positive FSCs. Per definition, FSCs are only collected from asymptomatic patients. However, there may have been differences in the baseline risks of patients that made the providers change treatment in select cases, thus potentially influencing the internal validity of the comparison between the outcomes in these 2 populations. We addressed this concern by performing a thorough review of the patient charts, finding no difference in disease risk based on baseline disease, previous infections, type of transplant, and immunosuppressive medications at time of the positive FSC. Other undocumented patient characteristics influencing antifungal management cannot be ruled out. Finally, the survey was constructed for this study and has not been previously validated. To address this potential cause of information bias, the questionnaire was formulated in a neutral manner to avoid influencing provider responses. The complete concordance between providers from the same institution further suggests that our results represent the reality of practice.
We suggest that FSCs are of limited clinical value in providing treatment guidance in pediatric HSCT patients. If FSCs are performed, stool cultures show the highest yield for identifying fungal colonization but might not predict the causative pathogen in IFDs. Further studies are needed to evaluate newer strategies of preemptive diagnosis, including routine use of imaging and serum fungal markers.
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